Association of Human Herpesvirus 6 and 8 in Relapsing Remitting Multiple Sclerosis Type during Exacerbation
- 1
- 2
- 3
- 4
- 5
Abstract
Multiple Sclerosis (MS) is a chronic demyelinating disease of the CNS with assumed autoimmune etiology. Human herpes viruses have probable effects on relapsing-remitting MS pathogenesis presumably through molecular mimicry and/or bystander mechanisms. In this study we probed the possible contribution of the two herpes viruses, human herpesvirus 6 (HHV-6) and human herpesvirus 8 (HHV-8), in clinically definite multiple sclerosis (CDMS) pa-tients-relapsing remitting type (RRMS) during clinical exacerbations. All patients had no history of immune modulating or suppressing drugs intake in the last 6 months. The peripheral blood samples, from CDMS patients (n = 20) (13F/7M, age (y) = 30.3 ± 3.21) and other immune mediated neurological disorders (OIND) (11F/9M, age = 25.2 ± 12.1), (My-asthenia Gravis, Guillain Barré Syndrome, ischemic stroke in adolescent and young adult with no clear risk factors), as a control group, had been enrolled within 15 months (January-2007-- March -2008). We investigated the existence of specific deoxyribonucleic acid (DNA) sequences belonging to HHV-6 and HHV-8, using polymerase chain reaction (PCR) in the isolated peripheral blood mononuclear cells (PBMCs) and in plasma. PCR demonstrated HHV-6 DNA in 7 cases (35%), HHV-8 sequences in only one cases (5%) in PBMCs from 20 relapsed CDMS patients; all HHV-6 posi-tive cases showed positive plasma results, while the blood samples from 20 OIND patients showed negative results ex-cept one case (5%) out of 9 cases of GBS was positive for HHV-8 in PBMCs. We consequently concluded that there is considerable evidence in this study that proposed the roles of HHV-6 and HHV-8 in MS pathogenesis and clinical ex-acerbation.
- D. E. McFarlin and H. F. McFarland, “Multiple Sclerosis,” The New England Journal of Medicine, Vol. 307, 1982, pp. 1183-1188.
- J. E. Friedman, M. J. Lyons, G. Cu, D. V. Ablashl, J. E. Whitman, M. Edgar, M. Koskiniemi, A. Vaheri and J. B. Zabriskie, “The Association of the Human Herpesvirus-6 and MS,” Multiple Sclerrosis, Vol. 5, No. 5, pp. 355-362.
- H. Lassmann, “Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis,” Springer Verlag, Berlin, 1983.
- J. F. Kurtzke, “Epidemiological Evidence for Multiple Sclerosis as an Infection,” Clinical Microbiology Review, Vol. 6, No. 4, 1993, pp. 382-427.
- S. S. Solden, R. Berti, N. Salem, et al., “Association of Human Herpes Virus 6 (HHV-6) With Multiple Sclerosis: Increased Igm Response to HHV-6 Early Antigen and Detection of Plasma HHV-6 DNA,” Nature Medicine, Vol. 3, 1997, pp. 1394-1397.
- S. F. Hunterand D. A. Hafler, “Ubiquitous Pathogens. Links between Infection and Autoimmunity in MS,” Neurology, Vol. 55, No. 2, 2000, pp. 164-165.
- A. K. Abbas, K. M. Murphy and A. Sher, “Functional Diversity of Helper T Lymphocytes,” Nature, Vol. 383, No. 6603, 1996, pp. 787-793.
- M. Allegretta, J. A. Nicklas and S. Sriram, R. J. Albertini and O. T. Abramsky, “Cells Responsive to Myelin Basic Protein in Patients with Multiple Sclerosis,” Science, Vol. 247, No. 4943, 1990, pp. 718-721.
- K. Bandobashi, M. Daibata, M. Kamioka, Y. Tanaka, I. Kubonishi, H. Taguchi, Y. Ohtsuki and I. Miyoshi, “Human Herpesvirus 6 (HHV-6)-Positive Burkitt’s Lymphoma: Establishment of a Novel Cell Line Infected with HHV-6,” Blood, Vol. 90, No. 3, 1997, pp. 1200-1207.
- W. L. McDonald, D. A. S. Compston, G. Edan, D. E. Goodkin, H. P. Hartung, F. D. Lublin, et al., “Diagnostic Criteria for MS: Guidelines from the International Panel on the Diagnosis of MS,” Annals of Neurology, Vol. 50, No. 1, 2001, pp. 121-127.
- C. M. Poser, D. W. Paty, L. Scheinberg, W. I. McDonald, F. A. Davis, G. C. Ebers, et al., “New Diagnostic Criteria for Multiple Sclerosis: Guidelines for Research Protocols,” Ann Neurol, Vol. 13, No. 2, pp. 227-231.
- S. Beer, K. M. R?sler and C. W. Hess, “Diagnostic Value of Paraclinical Tests In Multiple Sclerosis: Relative Sensitivities and Specificities for Reclassification According to the Poser Committee Criteria,” Journal of Neurology Neurosurgery Psychiatry, Vol. 59, No. 2, pp. 152-159.